本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 19 | 6 | 日~2026 | 年 | 6 月 | 18 | 日 | | 预计回购金额 | 万元~2,000 1,000 | | 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 股 176,421 | | | | | | | | 累计已回购股数占总股本比例 | 0.042% | | | | | | | | 累计已回购金额 | 5,041,082.86 | | | 元（不含交易费用和佣金） | | | | | 实际回购价格区间 | 元/股~29.61 27.82 | | ...

证券代码：688739 证券简称：成大生物 公告编号：2025-049 辽宁成大生物股份有限公司 关于召开 2025 年半年度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 3 日（星期三）至 9 月 9 日（星期二）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lncdsw@cdbio.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 辽宁成大生物股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日发布公 司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度 的经营成果、财务状况，公司计划于 2025 年 9 月 10 日上午 9:00-10:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 业绩说明会类型 本次投资者说明会以网络互动形式召开，公 ...

Summary of Key Points Core Viewpoint - Chengda Biological (688739.SH) has announced a share buyback program, indicating a commitment to returning value to shareholders and confidence in its financial health [1] Group 1: Share Buyback Details - As of August 31, 2025, the company has repurchased a total of 176,421 shares, which represents approximately 0.042% of the total share capital [1] - The highest price paid for the repurchased shares was 29.61 CNY per share, while the lowest price was 27.82 CNY per share [1] - The total amount spent on the buyback, excluding transaction fees and commissions, is 5,041,082.86 CNY [1]

Group 1 - The core point of the article is that Chengda Biological (Benxi) Co., Ltd. has obtained a patent for a device suitable for air-tightness testing in ultrafiltration systems, addressing issues related to air leakage risks and slow pressure relief in existing devices [1] - The patent, titled "A Device for Air-Tightness Testing Suitable for Ultrafiltration Systems," was granted with the announcement number CN 223272095 U, with an application date of November 2024 [1] - The company was established in 2021 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 100 million RMB [1] Group 2 - Chengda Biological (Benxi) Co., Ltd. has participated in 21 bidding projects and holds 32 patent records, along with 267 administrative licenses [1]

Core Viewpoint - The report provides a comprehensive overview of the fundraising activities and usage of funds by Liaoning Chengda Biological Co., Ltd. for the first half of 2025, highlighting the total amount raised, the allocation of funds, and the management of surplus funds [1][2][3]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was RMB 4,581,500,000, with all funds received by October 25, 2021 [1]. - As of June 30, 2025, the balance in the fundraising account was RMB 434,929,298.11, after utilizing RMB 1,423,828,419.14 for various projects [1][2]. Fund Usage and Management - The company has invested a total of RMB 783,049,371.27 from the raised funds, with specific allocations for projects such as the human vaccine construction project and the biological product research and development base [1][3]. - The company has established a fundraising management system to ensure the proper use and efficiency of the funds, adhering to relevant laws and regulations [1][3]. Project Investment and Adjustments - The company has made adjustments to its fundraising projects, including the completion of the human vaccine construction project and the initiation of cash management for idle funds, allowing for investment in safe financial products [3][4]. - A total of RMB 69,000,000 from over-raised funds was permanently allocated to supplement working capital [4][5]. Financial Management Practices - The company has not used idle funds for temporary working capital supplementation during the reporting period, ensuring that all funds are allocated according to the planned projects [3][4]. - The company has also engaged in cash management practices, allowing for the investment of up to RMB 1.6 billion in safe financial products, with a focus on maintaining liquidity and security [3][4]. Compliance and Reporting - The company has complied with all relevant regulations regarding the use and disclosure of fundraising activities, ensuring transparency and accountability in its financial practices [4][5]. - No violations of fundraising usage and management regulations were reported during the period [4][5].

Meeting Details - The shareholders' meeting of Liaoning Chengda Biological Co., Ltd. was held on August 28, 2025, in Shenyang, Liaoning Province [1] - A total of 223 ordinary shareholders attended the meeting, holding 240,348,641 voting rights, which accounts for 57.71% of the company's total voting rights [1] Voting Results - All proposed resolutions were passed with significant support from shareholders. For instance, the resolution regarding the election of Xu Biao as a non-independent director received 99.38% approval from ordinary shareholders [2] - The voting results for other resolutions also showed strong support, with percentages ranging from 98.63% to 99.38% in favor [2][2] Legal Compliance - The meeting was convened and conducted in accordance with the relevant laws and regulations, as confirmed by the attending lawyers [2][3]

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Liaoning Chengda Biotechnology Co., Ltd. in the first half of 2025, indicating a significant decline in revenue and profit due to market competition and changes in vaccine demand [3][4][13]. Company Overview and Financial Indicators - Liaoning Chengda Biotechnology Co., Ltd. is primarily engaged in the research, production, and sales of human vaccines, classified under the pharmaceutical manufacturing industry [3][4]. - The company reported a revenue of approximately 706.78 million yuan, a decrease of 19.75% compared to the same period last year [4][13]. - The total profit for the period was approximately 145.96 million yuan, down 46.37% year-on-year, with net profit attributable to shareholders at approximately 122.29 million yuan, a decline of 44.47% [4][13]. - The company's net assets decreased by 2.16% to approximately 9.36 billion yuan, and total assets fell by 2.64% to approximately 9.79 billion yuan [4][13]. Industry Context - The vaccine industry in China is undergoing structural adjustments and upgrades, with a dual management system focusing on public health strategies [6][7]. - The global vaccine market is experiencing rapid growth, with a projected compound annual growth rate of 9.5% due to increased demand and technological advancements [5][6]. - The domestic vaccine market is characterized by intense competition, with over 70 licensed companies, contrasting sharply with the oligopolistic structure seen in the international market [7][9]. Business Operations and Market Position - The company maintains a leading position in the domestic and international markets for human rabies vaccines, supported by a robust sales network and strategic marketing initiatives [11][12][13]. - The company is the only domestic producer of inactivated Japanese encephalitis vaccine, which is gaining market traction through enhanced promotion and distribution efforts [10][12][17]. - The company has a strong research and development pipeline, focusing on various vaccine products, including human diploid rabies vaccine and multi-valent influenza vaccines, to meet market demands [12][17]. Strategic Initiatives - The company is implementing a dual-driven model for domestic and international market expansion, leveraging a self-operated sales team and local partnerships [11][12][15]. - The marketing strategy emphasizes channel consolidation and terminal expansion, with a focus on increasing penetration in community hospitals and health clinics [15][16][17]. - The company is actively pursuing international market opportunities, particularly in developing countries, supported by the "Belt and Road" initiative [11][12][15].

Group 1 - The core viewpoint of the report indicates a decline in key financial metrics for the first half of 2025 compared to the same period in the previous year, highlighting challenges faced by the company [1][2] - Total assets at the end of the reporting period were approximately 9.79 billion RMB, a decrease of 2.64% from the previous year-end [1] - Operating revenue for the period was approximately 706.78 million RMB, reflecting a significant decline of 19.75% compared to 880.69 million RMB in the same period last year [1] - Total profit for the period was approximately 145.96 million RMB, down 46.37% from 272.15 million RMB in the previous year [1] - The net profit attributable to shareholders was reported at approximately 0.30 RMB per share, a decrease of 43.40% from the previous year [2] Group 2 - The company reported a weighted average return on net assets of 1.28%, down from 2.29%, indicating a decrease of 1.01 percentage points [1] - The number of shareholders at the end of the reporting period was 25,344 [2] - The actual controller of the company changed from the Liaoning Provincial State-owned Assets Supervision and Administration Commission to no actual controller as of February 28, 2025 [5]

Group 1 - The board of directors of Liaoning Chengda Biological Co., Ltd. held its 22nd meeting of the 5th session on August 28, 2025, with all 9 directors present, and the meeting was deemed legally valid [1][2]. - The board unanimously approved the proposal regarding the company's 2025 semi-annual report and its summary, with 100% of the votes in favor [1][2]. - The board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant laws and regulations, and ensuring no misuse of funds [2][3]. Group 2 - The board approved the semi-annual evaluation report of the 2025 quality improvement and efficiency enhancement action plan, with all votes in favor [2][3].

根据中国证券监督管理委员会于 2021 年 9 月 14 日出具的《关于同意辽宁成 大生物股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3019 号），公司首次公开发行人民币普通股（A）股 41,650,000.00 股，每股发行价格 为 110.00 元，募集资金总额为人民币 4,581,500,000.00 元；扣除发行费用 240,120,566.26 元，实际募集资金净额为人民币 4,341,379,433.74 元。上述募集资 金已于 2021 年 10 月 25 日全部到账，经容诚会计师事务所（特殊普通合伙）审 验，于 2021 年 10 月 25 日出具了《验资报告》（容诚验字[2021]110Z0015 号）。 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规及《公司章程》《募集资金管理制 度》等规范性文件的规定，辽宁成大生物股份 ...